maraviroc + pembrolizumab

Maraviroc + pembrolizumab is an investigational combination therapy consisting of two distinct agents with complementary mechanisms of action. Maraviroc is a small molecule antagonist of the C-C motif chemokine receptor 5 (CCR5), originally developed for HIV treatment, but also investigated for its immunomodulatory effects in cancer by inhibiting CCR5-mediated tumor-promoting pathways and reprogramming tumor-associated macrophages toward an antitumoral phenotype. Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. The combination has been studied in phase I clinical trials for refractory mismatch repair proficient (MMRp) or microsatellite stable colorectal cancer, aiming to overcome resistance to PD-1 blockade by modulating the tumor microenvironment through dual inhibition of CCR5 and PD-1 pathways[1][7].

Brand names

KeytrudaSelzentryCelsentri

Other names

pembrolizumab and maravirocPD-1 inhibition and CCR5 inhibitionPD1 inhibition and CCR5 inhibitionPD 1 inhibition and CCR5 inhibition